Answer
Preclinical investigations with idarucizumab have shown no interactions with prothrombin complex concentrates, including three-factor and four-factor PCCs and activated PCCs, although no formal interaction studies with Praxbind and other medicinal products have been performed.
Sources for this answer
- Praxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 12Document updated
Sources checked